BioSpace

BioSpace
  • 5.0 (3)
  • Life Sciences
  • Updated Weekly

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

  1. 5d ago

    Nordic biotech’s next act: From fragmentation to global force

    In this episode of Denatured, you’ll hear from Ester Sklarsky, principal at Sound Bioventures and João Ribas, partner at Novo Holdings Seed Investments. In this episode, we explore the diverging trajectories of Nordic biotech and what it will take for the region, including Norway and Finland, to compete more cohesively on the global stage. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Ester Sklarsky, Principal, Sound Bioventures João Ribas, Partner, Novo Holdings Seed Investments Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    Nordic biotech’s next act: From fragmentation to global force

  2. 6d ago

    Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2

    Second quarter earnings continue to roll with Novartis and Roche reporting this week; Eli Lilly’s AtaiBeckley buy for up to $3.8 billion offers clear “validation” for the fledgling psychedelics space; more drama unfolds at FDA as the agency goes back and forth on its policy of publishing complete response letters in real-time; and IPO fever continues.

    Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2

  3. Jul 16

    The future of pain relief: Exploring opioid alternatives

    In this episode of Denatured, you’ll hear from Lance Alstodt, chairman and CEO at Biorestorative Therapies, and Paul Mieyal, chief business officer at South Rampart Pharma. We explore why pain has remained such a difficult therapeutic area to tackle and one of the biggest unmet needs today, and how non-opioid mechanisms to regenerative therapies could reshape the future of treatment. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Lance Alstodt, Chairman & CEO, BioRestorative Therapies Paul Mieyal, Chief Business Officer, South Rampart Pharma Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    The future of pain relief: Exploring opioid alternatives

  4. Jul 15

    Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup

    Biogen’s new data, presented at the Alzheimer's Association International Conference, supports a tau-focused approach to the intractable neurodegenerative disease; psychedelics are back in the news with more positive data from Compass Pathways and final guidance from the FDA; and the ATTR-CM space got a major shakeup with the late-stage failure of AstraZeneca and Ionis’ antisense therapeutic.

    Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup

  5. Jul 14

    Bonus: Q2 2026 Job Market Update

    In this bonus episode, BioSpace Managing Editor Jef Akst and Angela Gabriel, content manager, life sciences careers, look at the Q2 job market and discuss encouraging signs for job seekers.

    Bonus: Q2 2026 Job Market Update

  6. Jul 10

    From sequence to scale: Gene editing’s new era in biologics manufacturing

    In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Jack Crawford, CEO, Demeetra Magnus Gustafsson, Chief Commercial Officer, NorthX Biologics Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    From sequence to scale: Gene editing’s new era in biologics manufacturing

  7. Jul 8

    Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil

    A surprising deal from Vertex Pharmaceuticals adds to Big Pharma’s acquisitive streak as Crinetics folds into the cystic fibrosis drugmaker. Meanwhile, IPOs and venture capital raises trend upward, but mostly for derisked companies. Plus, FDA decisions slow only slightly as the hunt for a permanent leader drags on.

    Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil

  8. Jul 1

    Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water

    The vibe at BIO 2026 in San Diego last week was overwhelmingly positive, with attendees observing noticeable changes at the FDA and an uptick in dealmaking and IPOs. Plus, a top medical journal this week retracted a pivotal study for Amgen’s rare disease drug Tavneos, which has been in the FDA’s crosshairs since January.

    Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
See All (250)

Ratings & Reviews

5
out of 5
3 Ratings

About

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Information

  • Creator
    BioSpace
  • Years Active
    2023 - 2026
  • Episodes
    250
  • Rating
    Clean
  • Copyright
    © 2026 BioSpace
  • Show Website
    BioSpace

You Might Also Like